Jump to content

Bivatuzumab mertansine

From Wikipedia, the free encyclopedia
Bivatuzumab mertansine
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD44 v6
Clinical data
ATC code
  • none
  • none
 ☒NcheckY (what is this?)  (verify)

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.[1]


  1. ^ Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. (October 2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical Cancer Research. 12 (20 Pt 1): 6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682.